Review Article
Volume 8 Issue 1
Christina Rahm*
July 02, 2026
Abstract
Insulin resistance is a primary pathologic process that causes type 2 diabetes mellitus, metabolic syndrome, cardiovascular disease, and associated endocrine disorders. Although pharmacologic therapy like metformin and insulin sensitizers are available, incomplete metabolic control, a significant number of the patient’s experiences adverse effects, or progressive disease. The reviewed patent invention in this white paper presents an innovative, combined approach to treatment of insulin resistance with eight proprietary formulations used following a time-based dose pattern. The method aims to solve the problem of insulin resistance as a multifactorial metabolic malfunction of disrupted glucose use, chronic inflammation, oxidative stress, micronutrient imbalance, and cellular signaling changes. The goal of the patented approach based on the combination of targeted nutraceutical compounds, botanical extracts, amino acids, minerals, and antioxidants is to restore insulin sensitivity, enhance metabolic biomarkers, and decrease the need to resort to traditional pharmacotherapy. This white paper is a scientific assessment of the rationale, design of formulation, treatment protocol, and possible clinical implications of the insulin resistance treatment methodology as patented.
References